These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38514215)

  • 1. Estimates of the lead time in screening for bladder cancer.
    Benbassat J
    Urol Oncol; 2024 Apr; 42(4):110-114. PubMed ID: 38514215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
    Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
    BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcome of home dipstick testing for hematuria.
    Madeb R; Messing EM
    World J Urol; 2008 Feb; 26(1):19-24. PubMed ID: 18040694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome of patients with a negative work-up for asymptomatic microhematuria.
    Madeb R; Golijanin D; Knopf J; Davis M; Feng C; Fender A; Stephenson L; Messing EM
    Urology; 2010 Jan; 75(1):20-5. PubMed ID: 19913883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A community study of bladder cancer screening by the detection of occult urinary bleeding.
    Britton JP; Dowell AC; Whelan P; Harris CM
    J Urol; 1992 Sep; 148(3):788-90. PubMed ID: 1512826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, Screening, and Prevention of Bladder Cancer.
    Lobo N; Afferi L; Moschini M; Mostafid H; Porten S; Psutka SP; Gupta S; Smith AB; Williams SB; Lotan Y
    Eur Urol Oncol; 2022 Dec; 5(6):628-639. PubMed ID: 36333236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility study of screening for bladder cancer with urinary molecular markers (the BLU-P project).
    Roobol MJ; Bangma CH; el Bouazzaoui S; Franken-Raab CG; Zwarthoff EC
    Urol Oncol; 2010; 28(6):686-90. PubMed ID: 21062653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force.
    Chou R; Dana T
    Ann Intern Med; 2010 Oct; 153(7):461-8. PubMed ID: 20921545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer.
    Cha EK; Tirsar LA; Schwentner C; Hennenlotter J; Christos PJ; Stenzl A; Mian C; Martini T; Pycha A; Shariat SF; Schmitz-Dräger BJ
    World J Urol; 2012 Dec; 30(6):847-52. PubMed ID: 23124847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome of hematuria home screening for bladder cancer in men.
    Messing EM; Madeb R; Young T; Gilchrist KW; Bram L; Greenberg EB; Wegenke JD; Stephenson L; Gee J; Feng C
    Cancer; 2006 Nov; 107(9):2173-9. PubMed ID: 17029275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
    Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
    Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
    Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
    Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A urine-based DNA methylation assay to facilitate early detection and risk stratification of bladder cancer.
    Ruan W; Chen X; Huang M; Wang H; Chen J; Liang Z; Zhang J; Yu Y; Chen S; Xu S; Hu T; Li X; Guo Y; Jiang Z; Chen Z; Huang J; Lin T; Fan JB
    Clin Epigenetics; 2021 Apr; 13(1):91. PubMed ID: 33902700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress towards a Nordic standard for the investigation of hematuria: 2019.
    Malmström PU; Skaaheim Haug E; Boström PJ; Gudjónsson S; Bjerggaard Jensen J
    Scand J Urol; 2019 Feb; 53(1):1-6. PubMed ID: 30636472
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective evaluation of fluorescence-in situ-hybridization to detect bladder cancer: results from the UroScreen-Study.
    Banek S; Schwentner C; Täger D; Pesch B; Nasterlack M; Leng G; Gawrych K; Bonberg N; Johnen G; Kluckert M; Gakis G; Todenhöfer T; Hennenlotter J; Brüning T; Stenzl A;
    Urol Oncol; 2013 Nov; 31(8):1656-62. PubMed ID: 22621963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the New American Urological Association Guidelines Risk Classification for Hematuria.
    Woldu SL; Ng CK; Loo RK; Slezak JM; Jacobsen SJ; Tan WS; Kelly JD; Lough T; Darling D; van Kessel KEM; de Jong JJ; van Criekinge W; Shariat SF; Hiar A; Brown S; Boorjian SA; Barocas DA; Svatek RS; Lotan Y
    J Urol; 2021 May; 205(5):1387-1393. PubMed ID: 33356483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
    Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
    Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of asymptomatic microscopic hematuria in adults.
    Sharp VJ; Barnes KT; Erickson BA
    Am Fam Physician; 2013 Dec; 88(11):747-54. PubMed ID: 24364522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microscopic hematuria as a screening marker for urinary tract malignancies.
    Sugimura K; Ikemoto SI; Kawashima H; Nishisaka N; Kishimoto T
    Int J Urol; 2001 Jan; 8(1):1-5. PubMed ID: 11168689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isomorphic red blood cells using automated urine flow cytometry is a reliable method in diagnosis of bladder cancer.
    Muto S; Sugiura S; Nakajima A; Horiuchi A; Inoue M; Saito K; Isotani S; Yamaguchi R; Ide H; Horie S
    Int J Clin Oncol; 2014 Oct; 19(5):928-34. PubMed ID: 24105457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.